Welcome to the international HTA database

Showing [22153 Records] Selected Records [0 Hits] [Clear]

Year	Source	Title
2020	Agency for Care Effectiveness (ACE)	Mycophenolate mofetil for immunosuppression
2020	Agency for Healthcare Research and Quality (AHRQ)	Strategies for patient, family, and caregiver engagement
2020	Institut national d'excellence en sante et en services sociaux (INESSS)	[State of knowledge: update of the systematic review of the effects of palivizumab prophylaxis on reducing complications associated with respiratory syncytial virus infections in children]
2020	The National Health Care Institute (ZIN, Zorginstituut Nederland)	Advice on a potential candidate for conditional inclusion of rhPTH 1-84 (Natpar®) in chronic hypoparathyroidism
2020	Agency for Care Effectiveness (ACE)	Adalimumab for treating inflammatory conditions
2020	Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S)	Paediatric cardiac surgery - literature review
2020	NIHR Health Technology Assessment programme	Home-based narrowband UVB, topical corticosteroid or combination for children and adults with vitiligo: HI-Light Vitiligo three-arm RCT
2020	The National Health Care Institute (ZIN, Zorginstituut Nederland)	GVS advice concerning romosozumab (Evenity®) for the treatment of severe osteoporosis
2020	Agency for Care Effectiveness (ACE)	Abiraterone for treating metastatic prostate cancer
2020	The National Health Care Institute (ZIN, Zorginstituut Nederland)	GVS assessment of amikacin liposome inhalation suspension (Arikayce® liposomal) for the treatment of NTM lung infections
2020	Austrian Institute for Health Technology Assessment (AIHTA)	Framework for reimbursement decisions of digital health technologies (mHealth) and its (retrospective) application on selected examples
2020	The National Health Care Institute (ZIN, Zorginstituut Nederland)	GVS assessment - extension of further conditions for nintedanib (Ofev®)
2020	NIHR Health Technology Assessment programme	Stratified Care for Patients with Sciatica and Suspected Sciatica in Primary Care: a randomised trial (the SCOPiC trial - SCiatica Outcomes in Primary Care)
2020	NIHR Health Technology Assessment programme	Medically unexplained symptoms(MUS): primary care intervention
2020	Austrian Institute for Health Technology Assessment (AIHTA)	Effectiveness of Music Therapy for Autism Spectrum Disorder, Dementia, Depression, Insomnia and Schizophrenia
2020	The National Health Care Institute (ZIN, Zorginstituut Nederland)	Package advice polatuzumab vedotin (Polivy®) in combination with bendamustine and rituximab (Pola-BR) for the treatment of r/r DLBCL
2020	The National Health Care Institute (ZIN, Zorginstituut Nederland)	GVS assessment of tafamidis (Vyndaqel®) for the treatment of wild-type or hereditary transthyretin amyloidosis
2020	Agency for Healthcare Research and Quality (AHRQ)	Therapies for clinically localized prostate cancer
2020	NIHR Health Technology Assessment programme	A randomised parallel group double blind placebo-controlled dose ranging Trial of low dose adjunctive alTeplase during priMary PCI (T-TIME)
2020	The National Health Care Institute (ZIN, Zorginstituut Nederland)	Advice on a potential candidate for conditional inclusion of ataluren (Translarna®) for Duchenne's muscular dystrophy
2020	Institut national d'excellence en sante et en services sociaux (INESSS)	[Report: iStent® and iStent inject® trabecular bypass for micro-invasive glaucoma surgery (MIGS)]
2020	The National Health Care Institute (ZIN, Zorginstituut Nederland)	GVS advice concerning siponimod (Mayzent®) for the treatment of secondary progressive multiple sclerosis
2020	The National Health Care Institute (ZIN, Zorginstituut Nederland)	Package advice venetoclax (Venclyxto®) in combination with obinutuzumab for the treatment of adult patients with previously untreated chronic lymphatic leukaemia (CLL)
2020	NIHR Health Technology Assessment programme	Pre-Operative Behavioural Intervention to Reduce Drinking before elective orthopaedic Surgery (Pre-Op BIRDS)
2020	Institut national d'excellence en sante et en services sociaux (INESSS)	[State of practice: prevention of cardiovascular events and safety of SGLT2 inhibitors compared to DPP-4 inhibitors in a real-world setting in patients with type 2 diabetes]
2020	The National Health Care Institute (ZIN, Zorginstituut Nederland)	GVS assessment of glucagon nasal powder (Baqsimi®) for the treatment of severe hypoglycaemia
2020	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Betibeglogene autotemcel (β-thalassaemia) (treatment costs)]
2020	NIHR Health Technology Assessment programme	Imiquimod versus podophyllotoxin, with and without human papillomavirus vaccine, for anogenital warts: the HIPvac factorial RCT
2020	NIHR Health Technology Assessment programme	Cancer diagnostic tools to aid decision-making in primary care: mixed-methods systematic reviews and cost-effectiveness analysis
2020	Penn Medicine Center for Evidence-based Practice (CEP)	Adverse effects of messenger RNA vaccines
2020	The National Health Care Institute (ZIN, Zorginstituut Nederland)	GVS assessment of ozanimod (Zeposia®) for the treatment of adult patients with relapsing-remitting multiple sclerosis (RRMS)
2020	Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S)	Amnion membrane for topical treatment of ophthalmic disorders, wound dressings for skin burns and ulcers on the craniofacial area, torso, and limbs
2020	Agency for Healthcare Research and Quality (AHRQ)	Treatment of depression in children and adolescents
2020	NIHR Health Services and Delivery Research programme	Identifying appropriate symbol communication aids for children who are non-speaking: enhancing clinical decision making
2020	Institut national d'excellence en sante et en services sociaux (INESSS)	[State of practice: evolving portrait of the use and clinical outcomes of transcatheter aortic valve implantation (TAVI) in Québec, an evaluation in the real-world context of care, 2013 to 2018]
2020	Penn Medicine Center for Evidence-based Practice (CEP)	Antibiotic prophylaxis for lower extremity wound debridement in the outpatient setting
2020	The National Health Care Institute (ZIN, Zorginstituut Nederland)	GVS assessment of amisulpride (Aktiprol®) for the treatment of schizophrenia
2020	Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S)	Alpha-1-antitrypsin genotyping
2020	NIHR Health Technology Assessment programme	Surgical fixation compared with cast immobilisation for adults with a bicortical fracture of the scaphoid waist: the SWIFFT RCT
2020	NIHR Health Technology Assessment programme	What is the effectiveness of varenicline compared with nicotine replacement therapy for long term smoking cessation and clinically important outcomes such as mortality, myocardial infarction and frequency of service use? Evidence from the Clinical Practice Research Datalink
2020	Institut national d'excellence en sante et en services sociaux (INESSS)	[Report: RebinynTM (nonacog beta pegol) – coagulation factor IX (recombinant), notice of inclusion on the Liste des produits du système du sang du Québec]
2020	Penn Medicine Center for Evidence-based Practice (CEP)	Point of care vascular ultrasound
2020	The National Health Care Institute (ZIN, Zorginstituut Nederland)	Package advice esketamine nasal spray (Spravato®) for the treatment of adults with treatment-resistant major depressive disorder
2020	Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S)	PSMA PET/CT imaging for informing treatment of patients with prostate cancer
2020	Agency for Healthcare Research and Quality (AHRQ)	Treatments for acute pain: a systematic review
2020	Institut national d'excellence en sante et en services sociaux (INESSS)	[Report: recommendations concerning the information required to monitor nusinersen use in real-world settings]
2020	Penn Medicine Center for Evidence-based Practice (CEP)	Early mobilization to reduce medical inpatient length of stay and adverse
2020	The National Health Care Institute (ZIN, Zorginstituut Nederland)	Trastuzumab-emtansine (Kadcyla®) in adjuvant treatment of adult patients with HER-2 positive breast cancer in an early stage
2020	Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S)	Arthroscopic injection of a bioadhesive hydrogel implant (JointRep), in conjunction with microfracture, for treatment of osteochondral defects of the knee
2020	The National Health Care Institute (ZIN, Zorginstituut Nederland)	Indacaterol/glycopyrronium/mometasone (Enerzair® Breezhaler®) for maintenance treatment of asthma in adult patients
2020	Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S)	Review of immunoglobulin use for primary immunodeficiency diseases with antibody deficiency
2020	NIHR Health Services and Delivery Research programme	Identifying nurse-staffing requirements using the Safer Nursing Care Tool. Modelling the costs and consequences of real world application to address variation in patient need on hospital wards
2020	The National Health Care Institute (ZIN, Zorginstituut Nederland)	Atectura® Breezhaler® (indacaterol acetate/mometasone furoate)
2020	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Burosumab (reassessment after the deadline: hypophosphataemia)]
2020	The National Health Care Institute (ZIN, Zorginstituut Nederland)	Advice reassessment osimertinib (Tagrisso®)
2020	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Burosumab (new therapeutic indication: X-linked hypophosphataemia, ≥ 18 years)]
2020	NIHR Health Technology Assessment programme	Seasonal Influenza Vaccination Effectiveness II (SIVE II): use of a large national primary care and laboratory-linked dataset to evaluate live attenuated and trivalent inactivated influenza vaccination effectiveness
2020	NIHR Public Health Research (PHR) programme	Feasibility study of how best to engage obese men in narrative SMS (short message system) and incentive interventions for weight loss, to inform a future effectiveness and cost-effectiveness trial
2020	NIHR Health Technology Assessment programme	Point-of-care creatinine tests to assess kidney function for outpatients requiring contrast-enhanced CT imaging: systematic reviews and economic evaluation
2020	The National Health Care Institute (ZIN, Zorginstituut Nederland)	Avelumab in combination with axitinib as a first-line treatment for adult patients with advanced renal cell carcinoma
2020	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Cannabidiol - reassessment after expiry of the deadline (Dravet-Syndrome, ≥ 2 years, combination with clobazam)]
2020	The National Health Care Institute (ZIN, Zorginstituut Nederland)	GVS assessment of ivacaftor/tezacaftor (Symkevi®) in combination with ivacaftor (Kalydeco®) for the treatment of cystic fibrosis
2020	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Cannabidiol - reassessment after expiry of the deadline (Lennox-Gastaut-Syndrome, ≥ 2 years, combination with clobazam)]
2020	NIHR Public Health Research (PHR) programme	Healthy Dads, Healthy Kids UK: a cultural adaptation and feasibility study of a weight management programme for fathers of younger children
2020	The National Health Care Institute (ZIN, Zorginstituut Nederland)	Ibrutinib (Imbruvica®) for the treatment of Waldenstrom's disease
2020	NIHR Health Services and Delivery Research programme	An evaluation of alcohol treatment centres: implications for service delivery, patient benefit and harm reduction
2020	Swiss Federal Office of Public Health (FOPH)	Glinides and glitazones in the treatment of type 2 diabetes
2020	Andalusian Health Technology Assessment Area (AETSA)	[Effectiveness and safety of the macrobiotic diet]
2020	The National Health Care Institute (ZIN, Zorginstituut Nederland)	Ibrutinib (Imbruvica®) for the treatment of adult patients with previously untreated chronic lymphatic leukaemia (CLL)
2020	NIHR Health Technology Assessment programme	Spironolactone to improve exercise tolerance in people with permanent atrial fibrillation and preserved ejection fraction: the IMPRESS-AF RCT
2020	The National Health Care Institute (ZIN, Zorginstituut Nederland)	GVS assessment of Trifarotene (50 microgram/gram cream) (Aklief®) for the cutaneous treatment of acne vulgaris on the face and torso in patients aged 12 years and over
2020	NIHR Health Technology Assessment programme	Examining the benefit of graduated compression stockings as an adjunct to low dose low molecular weight heparin in the prevention of venous thromboembolism in elective surgical inpatients identified as moderate or high risk for venous thromboembolism a multi-centre randomised controlled trial
2020	NIHR Health Services and Delivery Research programme	Understanding how frontline staff use patient experience data for service improvement - an exploratory case study evaluation and national survey (US-PEx)
2020	The National Health Care Institute (ZIN, Zorginstituut Nederland)	Package advice dabrafenib/trametinib (Tafinlar®/Mekinist®)
2020	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Sleep position therapy for obstructive sleep apnoea]
2020	Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S)	Amnion membrane for topical treatment of ophthalmic disorders (caused by disease and/or trauma), and wound dressings for skin burns and ulcers on the craniofacial area, torso, and limbs
2020	NIHR Health Services and Delivery Research programme	Young people with Attention Deficit Hyperactivity Disorder (ADHD) in transition from children's services to adult services (Catch-uS): a mixed methods project using national surveillance, qualitative and mapping studies
2020	Norwegian Institute of Public Health (NIPH)	[Hyperbaric oxygen therapy for radiation-induced cystitis]
2020	The National Health Care Institute (ZIN, Zorginstituut Nederland)	GVS assessment of oral semaglutide (Rybelsus®)
2020	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Gilteritinib (Relapsed or Refractory Acute Myeloid Leukaemia with an FLT3 Mutation)]
2020	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Sleep position therapy for obstructive sleep apnoea - Addendum to commission E20-07]
2020	The National Health Care Institute (ZIN, Zorginstituut Nederland)	Pentosan polysulfate sodium (Elmiron®) for the treatment of bladder pain syndrome characterized by either glomerulations or Hunner’s lesions
2020	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Givosiran (acute hepatic porphyria, ≥ 12 years)]
2020	The National Health Care Institute (ZIN, Zorginstituut Nederland)	12 SQ-HDM SLIT (Itulazax®) for the treatment of allergic rhinitis or conjunctivitis induced by pollen from the birch homologous group
2020	The National Health Care Institute (ZIN, Zorginstituut Nederland)	Olaparib (Lynparza®) for the maintenance treatment of adult patients with carcinoma of the ovaries, tubes or peritoneum (package advice)
2020	Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S)	Review of immunoglobulin use for primary immunodeficiency diseases with antibody deficiency
2020	Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU)	[Pharmacological treatment of common pain conditions in older persons]
2020	The National Health Care Institute (ZIN, Zorginstituut Nederland)	Trientine tetrahydrochloride (Cuprior®) [for] the treatment of Wilson's disease
2020	The National Health Care Institute (ZIN, Zorginstituut Nederland)	GVS assessment of hydroquinine (Inhibin®) for patients with nocturnal muscle cramps
2020	European Network for Health Technology Assessment (EUnetHTA)	Polatuzumab vedotin in combination with bendamustine and rituximab for the treatment of relapsed/refractory diffuse large B-cell lymphoma (DLBCL) who are not candidates for haematopoietic stem cell transplant
2020	The National Health Care Institute (ZIN, Zorginstituut Nederland)	Voretigene neparvovec (Luxturna®) for the treatment of vision loss due to inherited retinal dystrophy with bi-allelic RPE65 mutations (package advice)
2020	The National Health Care Institute (ZIN, Zorginstituut Nederland)	Bevespi® aerosphere 7.2 micrograms / 5 micrograms
2020	European Network for Health Technology Assessment (EUnetHTA)	Siponimod for the treatment of adult patients with secondary progressive multiple sclerosis (SPMS) with active disease evidenced by relapses or imaging features of inflammatory activity
2020	Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S)	3D printing applications in healthcare
2020	NIHR Health Services and Delivery Research programme	Patient Experience And Reflective Learning (PEARL)
2020	European Network for Health Technology Assessment (EUnetHTA)	Brolucizumab for the treatment of adults with neovascular (wet) age-related macular degeneration (AMD)
2020	Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S)	Technologies for the diagnosis of prostate cancer
2020	European Network for Health Technology Assessment (EUnetHTA)	Crizanlizumab for the prevention of vaso-occlusive crises in sickle cell disease patients aged 16 years and older
2020	NIHR Health Services and Delivery Research programme	How do different neurodisability services meet the psychosocial support needs of children/young people with feeding disabilities and their families: a national survey and case study approach to mapping and costing service models, care pathways and the child and family experience
2020	European Network for Health Technology Assessment (EUnetHTA)	Cefiderocol for the treatment of infections due to aerobic gram-negative bacteria in adult patients with limited treatment options